Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744
CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI
1744 CL. Olodaterol dose 40 mcg was investigated only in the open-label extension part for
additional PK assessments which are not defined as primary or secondary endpoints.